Assessing racial disparities in testicular cancer survival: Evidence from a nationwide cohort.
Cancer Survival
DOI:
10.1200/jco.2025.43.5_suppl.621
Publication Date:
2025-02-18T14:30:51Z
AUTHORS (12)
ABSTRACT
621 Background: Testicular cancer is one of the most common and curable malignancies in young men, with a 5 year survival rate 95%. Limited research has explored long-term outcomes among Black given rarity disease this demographic. Our study aims to assess potential racial differences overall (OS) cancer-specific mortality (CSM) testicular patients using large, equal access nationwide Veterans Affairs (VA) database, focusing on self-identified White race. Methods: This retrospective analyzed from VA database utilizing Informatics Computing Infrastructure (VINCI). Self-identified race was obtained Cancer Registry, OS CSM as primary outcomes. identified National Death Index (NDI). NDI data available through 12/31/2020, after which date all continued follow-up were censored. Cox proportional hazard models applied examine associations CSM, adjusting for relevant clinical factors such staging, Charlson Comorbidity (CCI), receipt adjuvant chemotherapy or radiation. All time event analyses done diagnosis outcome interest. Results: We compared 1799 118 patients. A total 431 (22.49%) died, whom 405 26 Black. There no statistically significant difference at 10 years between individuals (80.4% vs 81.6%, p = 0.68). The multivariable cox-regression analysis showed men. Of deaths, 72 (71 White, 1 Black). 10-year cumulative incidence (0% 4.1%, p=0.12). Similarly, found men analysis. Conclusions: disparities healthcare system. As represents an care setting, these findings may not be generalizable broader U.S. population, where are more notable. Conversely, overcome known sociodemographic that drive worse limited by small number experiencing Future should conducted validate association diverse settings.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....